



YUNKANG GROUP LIMITED

云康集团有限公司

Yunkang Group Wins Three Major Awards at 7th China IR Annual Awards

(Hong Kong, 12 January 2024) – **Yunkang Group Limited** (Yunkang or the “Group”; Stock Code: 2325), a leading medical operation service provider in China, has won the following three major awards at the 7th China IR Annual Awards:

- **“Best Digital Investor Relations Award”**
- **“Best Leadership Award” - Mr. Lin Yingjia, Vice President, Secretary of the Board, and Chief Financial Officer**
- **“Best Director Award” - Ms. Venus Zhao, General Manager of Hong Kong Office, General Manager of Capital Markets and Corporate Communications**

As one of the most influential awards in the investor relations field in China, “China IR Annual Awards” is the only annual award that focuses on frontline IR practitioners in listed companies and outstanding IR projects, commending IR teams and individual practitioners in listed companies for their excellent contribution to promoting industry transformation and development. A total of 273 listed companies participated in the latest selection and 744 award submissions were received.

Since entering the capital market, Yunkang has placed much emphasis on meeting the demands of domestic and overseas shareholders, and promoting healthy development of its shareholders relations. It attaches importance to efficient communication with shareholders. In 2023, it conducted online and offline results briefings, investor site visits, and investor roadshows, and actively participated in more than 140 investor conferences, to keep shareholders and potential shareholders informed of and enhance their confidence in the Company. In the communications with investors, Yunkang adheres to the IR philosophy of being objective and candid, so as to help investors grasp a full picture of the Company’s situation, directing their focus to the fundamentals of the Company and the industry. The Company issues contents and announcements of interest to investors and has continued to optimize and enrich the content of its IR and Social, Environmental and Governance pages on its official website. Through communicating with investors effectively, the Company has provided investors with substantive value and built solid investor relationship.

Since 2022, Yunkang has successively launched 10 digital operation platforms, and its IR team has keenly embraced digitalization and utilized diverse digital tools and platforms to organize investor activities, such as online results announcement conferences, roadshows and one-on-one meetings. Using digital tools has enabled the Company to achieve more convenient and effective investor engagement and conversion, as well as boosting participation of target investors. Yunkang will continue to listen to feedback from the capital market, maintain close communication with value investors worldwide, and create more value for shareholders and society.



Ms. Venus Zhao, General Manager of Hong Kong Office and General Manager of Capital Markets and Corporate Communications, receives the awards on behalf of the Group



Yunkang Group wins the “Best Director Award”, “Best Digital Investor Relations Award” and “Best Leadership Award” at 7th China IR Annual Awards

Mr. Lin Yingjia, Vice President, Secretary of the Board of Directors and Chief Financial Officer of Yunkang Group Limited, stated that the Company has been honored with three awards for its excellent IR work, which fully recognized Yunkang’s endeavors and achievements in the capital market and investor relations. In the future, Yunkang will take on the industry affirmation and encouragement, continuously improve corporate governance and further strengthen its IR efforts, so as to efficiently, accurately, completely and timely deliver its investment value to investors, the public and regulators, achieving value dissemination and contributing to further development of the industry.

– End –

Yunkang Group Limited (Stock Code : 2325)

Yunkang Group is a leading medical operation service provider in China, which started to provide standardized medical diagnostic services to medical institutions at all levels as early as 2008. Leveraging its own professional diagnostic capabilities and the nationwide service network of integrated healthcare systems, Yunkang has gradually grown to become a medical operation service platform. Meanwhile, Yunkang is a medical operation service provider in China offering a full suite of diagnostic testing services which are diagnostic outsourcing services and diagnostic testing services for medical institution alliances. Yunkang provides diagnostic services through on-site diagnostic centers to collaborative hospitals in the integrated healthcare systems in China and assists them in improving their clinical diagnosis capabilities through co-developing diagnostic centers. As of June 30, 2023, Yunkang has successfully provided professional services to 410 medical institution alliances and the hospitals we collaborated with were located across 31 provinces and municipalities in China.

Media Inquiries

Yunkang Group Ltd

Venus Zhao General Manager of Hong Kong Office, General Manager of Capital Markets and Corporate Communication

E-mail: zhaohui@yunkanghealth.com

Website: www.yunkanghealth.com

Strategic Financial Relations Limited

Angelus Lau / Holly Szeto / Shannon Lei

Tel: 2864 4805 / 2864 4859 / 2114 2881

E-mail: angelus.lau@sprg.com.hk / holly.szeto@sprg.com.hk / shannon.lei@sprg.com.hk

Website: www.sprg.com.hk